Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $66.73 which represents a slight increase of $3.92 or 6.24% from the prior close of $62.81. The stock opened at $63.08 and ...

In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a ...

While it might not perfectly follow in the larger biotech's footsteps, TERN-601 has the potential to be one of the safer, ...

Jim Cramer is probably the closest thing we have to stock market superstar influencer. The host of CNBC’s “Mad Money” show is ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

2. The potential business rivals are Roche, Amgen, Pfizer, AstraZeneca, and Boehringer, as well as acquisition targets including Viking Therapeutics and Structure Therapeutics. 3. The market says Novo ...

Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX), for ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $60.83 which represents a slight increase of $6.18 or 11.31% from the prior close of $54.65. The stock opened at $57.23 and ...

Rivals Eli Lilly and Viking Therapeutics also rose. Write to Rob Curran at [email protected] About Dow Jones Newswires Dow Jones Newswires is a market-moving financial and business news source, ...